The role of vitamin D deficiency in the pathogenesis of osteoporosis and in the modulation of the immune system in HIV-infected patients

Clinical Reviews in Bone and Mineral Metabolism

Volumn 10, Issue 4, 2012, Pages 277-287

  Ross, Allison C ^a,b   McComsey, Grace A ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

1,25 Dihydroxyvitamin D; 25 Hydroxyvitamin D; Bone mineral density; HIV; Immune restoration; Immune system; Osteopenia; Osteoporosis; Vitamin D deficiency

Indexed keywords

VITAMIN D;

ARTICLE; BONE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; RISK FACTOR; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY;

EID: 84874477934     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-012-9131-0     Document Type: Article

References (101)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review [see comment]. AIDS. 2006;20(17):2165-74. (Pubitemid 44684707)
2. Mora S, et al. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15(14):1823-9. (Pubitemid 32939243)
3. O'Brien KO, et al. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr. 2001;73(4):821-6. (Pubitemid 32239238)
4. Mehta S, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS ONE. 2010;5(1):e8770.
5. Mehta S, et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J Infect Dis. 2009;200(7):1022-30.
6. Viard JP, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011;25(10):1305-15.
7. Campbell GR, Spector SA. Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem. 2011;286(21):18890-902.
8. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81. (Pubitemid 47080391)
9. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24(12):1017-29. (Pubitemid 350145410)
10. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062-72. (Pubitemid 44162310)
11. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248-54.
12. Holick MF. Perspective on the impact of weightlessness on calcium and bone metabolism. Bone. 1998;22(5 Suppl):105S-11S. (Pubitemid 28223266)
13. Thomas MK, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777-83. (Pubitemid 28135983)
14. Holick MF, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30.
15. Institute of Medicine (U.S.). Dietary reference intakes for calcium and vitamin D. The National Academies Press, Washington, DC. 2011.
16. Van Den Bout-Van Den Beukel CJ, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24(11):1375-82.
17. Mueller NJ, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24(8):1127-34.
18. Ross A, et al. Traditional risk factors overshadow HIV-related factors in predicting vitamin D deficiency in HIV-infected children and young adults (abstract O-10). In 13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV 2011. Rome, Italy.
19. Rodriguez M, et al. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9-14.
20. Stein EM, et al. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int. 2011;22(2):477-87.
21. Welz T, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24(12):1923-8.
22. Garcia Aparicio AM, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006;25(4):537-9. (Pubitemid 44137629)
23. Stephensen CB, et al. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83(5):1135-41. (Pubitemid 44713115)
24. Ross AC, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther. 2011;16(4):555-63.
25. Rutstein R, et al. Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr. 2011;30(5):624-8.
26. Dao CN, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52(3):396-405.
27. Haug C, et al. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169(4):889-93. (Pubitemid 24102128)
28. Atkinson S, et al. Vitamin D deficiency in children with perinatally acquired HIV-1 infection living in the UK (abstract P159). In British HIV Association 2010. Manchester, UK.
29. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425-9.
30. Longenecker C, et al. Vitamin D supplementation and endothelial function among vitamin D deficient HIV-infected persons: a randomized placebo-controlled trial. Antiviral Therapy (in press).
31. Wohl D, et al. Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naïve adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial (abstract 79LB). In 18th Conference on Retroviruses and Opportunistic Infections 2011. Boston, MA.
32. Cozzolino M, et al. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513-20. (Pubitemid 36293104)
33. Gyllensten K, et al. Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS. 2006;20(14):1906-7. (Pubitemid 44358915)
34. Barrett JS, et al. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther. 2002;40(11):507-19. (Pubitemid 35331935)
35. Landriscina M, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer. 2008;122(12):2842-50. (Pubitemid 351631388)
36. Ellfolk M, et al. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009;75(6):1392-9.
37. Herzmann C, Arasteh K. Efavirenz-induced osteomalacia. AIDS. 2009;23(2):274-5.
38. Zhou C, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest. 2006;116(6):1703-12.
39. Welz T, Childs K, Post FA. Do nevirapine and efavirenz affect vitamin D homeostasis similarly? AIDS. 2011;25(6):875-6.
40. Gafni RI, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118(3):e711-8. (Pubitemid 46089998)
41. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19(17):2031-3. (Pubitemid 41669029)
42. Gallant JE, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201. (Pubitemid 38917996)
43. Hazra R, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116(6):e846-54. (Pubitemid 46056464)
44. Jones S, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19(7):913-8.
45. McComsey GA, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-801.
46. Calmy A, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200(11):1746-54.
47. Rosenvinge MM, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54(5):496-9.
48. Havens P, et al. Vitamin D3 supplementation decreases PTH in HIV-infected youth being treated with TDF-containing combination ART: a randomized, double-blind, placebo-controlled multicenter trial: adolescent trials network study 063 (abstract 80). In 18th Conference on Retroviruses and Opportunistic Infections 2011. Boston, MA.
49. Childs KE, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26(8):855-9.
50. Bongiovanni M, et al. Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr. 2005;40(4):503-4. (Pubitemid 41669189)
51. Fausto A, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893-7. (Pubitemid 44500653)
52. Mondy K, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482-90. (Pubitemid 36241317)
53. Bischoff-Ferrari HA, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257-64. (Pubitemid 40629192)
54. Dawson-Hughes B, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670-6. (Pubitemid 27375473)
55. Jackson RD, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-83. (Pubitemid 43247138)
56. El-Hajj Fuleihan G, et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab. 2006;91(2):405-12. (Pubitemid 43236902)
57. Winzenberg TM, et al. Vitamin D supplementation for improving bone mineral density in children. Cochrane Database Syst Rev; 2010(10), p. CD006944.
58. Tebas P, et al. Initiation of ART is associated with bone loss independent of the specific ART regimen: results of ACTG A5005 s (abstract 837). In 14th Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles, CA.
59. Grund B, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23(12):1519-29.
60. Brown TT, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5):554-61.
61. Tebas P, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14(4):F63-7. (Pubitemid 30182458)
62. Bruera D, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17(13):1917-23. (Pubitemid 37070277)
63. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91(8):2938-45. (Pubitemid 44271739)
64. Guillemi S, et al. Prevalence of bone mineral density abnormalities and related risk factors in an ambulatory HIV clinic population. J Clin Densitom. 2010;13(4):456-61.
65. Paul TV, et al. Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy. Endocr Pract. 2010;16(4):547-53.
66. Hileman C, et al. Bone mineral density (BMD), vitamin D levels and inflammation markers in antiretroviral-naïve HIV-infected and uninfected adults (abstract 880). In 19th Conference on Retroviruses and Opportunistic Infections 2012. Seattle, WA.
67. Ramayo E, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2005;21(11):915-21. (Pubitemid 41785776)
68. McComsey GA, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21(18):2473-82. (Pubitemid 350145179)
69. Mondy K, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38(4):426-31. (Pubitemid 40381552)
70. + children and adolescents after bi-monthly supplementation with oral cholecalciferol and calcium (abstract 707). In: 18th Conference on Retroviruses and Opportunistic Infections 2011. Boston, MA.
71. Wang TT, et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005;19(11):2685-95. (Pubitemid 41577243)
72. Wilkinson RJ, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000;355(9204):618-21. (Pubitemid 30099469)
73. Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax. 1985;40(3):187-90. (Pubitemid 15108303)
74. Cannell JJ, et al. Diagnosis and treatment of vitamin D deficiency. Exp Opin Pharmacother. 2008;9(1):107-18. (Pubitemid 351233752)
75. Rehman PK. Sub-clinical rickets and recurrent infection. J Trop Pediatr. 1994;40(1):58.
76. Williams B, Williams AJ, Anderson ST. Vitamin D deficiency and insufficiency in children with tuberculosis. Pediatr Infect Dis J. 2008;27(10):941-2.
77. Muhe L, et al. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet. 1997;349(9068):1801-4. (Pubitemid 27257557)
78. Khazai N, Judd SE, Tangpricha V. Calcium and vitamin D: skeletal and extraskeletal health. Curr Rheumatol Rep. 2008;10(2):110-7.
79. van Etten E, et al. Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev. 2008;66(10 Suppl 2):S125-34.
80. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl). 2010;88(5):441-50.
81. Liu PT, Krutzik SR, Modlin RL. Therapeutic implications of the TLR and VDR partnership. Trends Mol Med. 2007;13(3):117-24. (Pubitemid 46341960)
82. Yuk JM, et al. Vitamin D3 induces autophagy in human monocytes/ macrophages via cathelicidin. Cell Host Microbe. 2009;6(3):231-43.
83. Bergman P, et al. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res. 2007;5(4):410-5. (Pubitemid 47040482)
84. Frohm Nilsson M, et al. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun. 1999;67(5):2561-6.
85. Levinson P, et al. Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS. 2009;23(3):309-17.
86. Mahon BD, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem. 2003;89(5):922-32. (Pubitemid 36927724)
87. Bhalla AK, et al. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol. 1984;133(4):1748-54. (Pubitemid 14035260)
88. Lemire JM, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125(6 Suppl):1704S-8S.
89. Mattner F, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol. 2000;30(2):498-508. (Pubitemid 30098842)
90. Schleithoff SS, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial.[see comment]. Am J Clin Nutr. 2006;83(4):754-9. (Pubitemid 44713136)
91. van Etten E, et al. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol. 2007;37(2):395-405. (Pubitemid 46915579)
92. Mehta S, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 5(1): p. e8770.
93. Viard J, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011;25(10):1305-15.
94. de Luis DA, et al. Relation among micronutrient intakes with CD4 count in HIV infected patients. Nutr Hosp. 2002;17(6):285-9. (Pubitemid 44616131)
95. Teichmann J, et al. Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism. 2000;49(9):1134-9.
96. Arpadi SM, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009;123(1):e121-6.
97. Kakalia S, et al. Vitamin D Supplementation and CD4 Count in Children Infected with Human Immunodeficiency Virus. L Pediatr. 2011;159(6):951-7.
98. Haug CJ, et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83(11):3832-8. (Pubitemid 28513558)
99. Madeddu G, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48(1):39-48. (Pubitemid 39069663)
100. Haug CJ, et al. Disseminated Mycobacterium avium complex infection in AIDS: immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin D. J Infect Dis. 1996;173(1):259-62. (Pubitemid 26006830)
101. Kuehn EW, et al. Hypocalcaemia in HIV infection and AIDS. J Intern Med. 1999;245(1):69-73. (Pubitemid 29049145)